ロード中...
Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence
Tenofovir alafenamide (TAF), a novel prodrug of tenofovir was developed to deliver enhanced antiviral potency and reduced systemic toxicities by more efficient intracellular delivery of the active metabolite tenofovir disphosphate than tenofovir disoproxil fumarate (TDF). In two randomized, double-b...
保存先:
| 出版年: | Therap Adv Gastroenterol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6048601/ https://ncbi.nlm.nih.gov/pubmed/30034532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284818786108 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|